| Bioactivity | JBI-589 is a non-covalent PAD4 isoform-selective inhibitor. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors[1]. |
| Name | JBI-589 |
| CAS | 2308504-22-3 |
| Formula | C29H28FN5O |
| Molar Mass | 481.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Deng H, et al. A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. Cancer Res. 2022 Oct 4;82(19):3561-3572. [2]. Gajendran C, et al. Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4. Sci Rep. 2023 Feb 23;13(1):3189. |